Shares of Glenmark Prescription drugs Ltd surged 1.5% to the touch a day’s excessive of Rs 1,509 on twenty first March after the agency introduced that its subsidiary, Glenmark Prescription drugs Inc., USA, has obtained closing approval from the US Meals & Drug Administration (USFDA) for its Olopatadine Hydrochloride Ophthalmic Answer USP, 0.2% (OTC).
Glenmark’s product is bioequivalent to Pataday As soon as Day by day Aid Ophthalmic Answer, 0.2% (OTC), developed by Alcon Laboratories, Inc.
Glenmark Therapeutics Inc., USA, will distribute the product within the US, strengthening its ophthalmic portfolio.
The Pataday 0.2% (OTC) market recorded annual gross sales of roughly $50.7 million as of twenty second February 2025, per Nielsen information.
Marc Kikuchi, President & Enterprise Head of North America, emphasised the agency’s dedication to increasing its OTC ophthalmic portfolio.
He said that including Olopatadine Hydrochloride Ophthalmic Answer 0.2% displays Glenmark’s give attention to market wants and high quality OTC merchandise.
At 11:09 AM, the shares of Glenmark Pharma had been buying and selling 1.34% greater at Rs 1,498.65 on NSE.
Curious About Glenmark Pharma? Ask the Analyst.
Prepared to take a position like a professional? Unicorn Alerts app equips you with 100+ Free instruments and information you want to succeed. Obtain the Unicorn Alerts app and acquire entry to every day inventory lists and insightful market evaluation and far more!
